QIAGEN (NYSE:QGEN) announced its quarterly earnings results on Sunday. The company reported $0.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.03, MarketWatch Earnings reports. QIAGEN had a return on equity of 17.51% and a net margin of 11.18%. During the same quarter in the prior year, the business posted $0.34 earnings per share.
QGEN traded up $0.32 on Tuesday, hitting $47.94. 1,460,727 shares of the company traded hands, compared to its average volume of 850,952. The company has a 50 day moving average of $50.11 and a 200-day moving average of $50.93. The company has a quick ratio of 1.22, a current ratio of 1.46 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $10.93 billion, a PE ratio of 58.73, a PEG ratio of 1.29 and a beta of 0.41. QIAGEN has a 12-month low of $41.48 and a 12-month high of $59.00.
A number of brokerages have issued reports on QGEN. Nord/LB reaffirmed a “neutral” rating on shares of QIAGEN in a report on Wednesday, January 6th. Norddeutsche Landesbank reaffirmed a “hold” rating on shares of QIAGEN in a report on Wednesday, January 6th. DZ Bank reaffirmed a “neutral” rating on shares of QIAGEN in a report on Wednesday, April 7th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of QIAGEN in a report on Tuesday. Finally, Berenberg Bank reissued a “buy” rating on shares of QIAGEN in a report on Friday, February 19th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. QIAGEN presently has a consensus rating of “Buy” and an average target price of $59.92.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Receive News & Ratings for QIAGEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QIAGEN and related companies with MarketBeat.com's FREE daily email newsletter.